News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:
   

3SBio (SSRX) Acquires CDMO Business From Canada's Therapure For $290 Million



9/5/2017 1:21:24 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
3SBio of Shenyang will pay $290 million to acquire the biologic contract development and manufacturing operations of Therapure, a Toronto area biopharma focused on plasma drugs. 3SBio formed a JV with CPE Funds, the private equity arm of CITIC, to complete the purchase. Therapure will spin off its plasma-based drug manufacturing and commercialization operations into a new company, called ProductsCo. In addition to the $290 million purchase price, 3SBio/CPE will contribute $16-$20 million to ProductsCo for the construction of a manufacturing facility. 3SBio, a China innovative biologic drug company, positioned the acquisition as a move into a new market that will provide the opportunity for future alliances with North American biopharmas

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES